---
title: "Western Securities: Winner Medical's growth driven by both internal and external factors, maintaining a \"Buy\" rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244018306.md"
description: "Western Securities released a research report, believing that Winner Medical has entered a growth year driven by both medical and consumer sectors. The company plans to launch an equity incentive plan in 2024, granting 7.476 million restricted shares, with performance assessment targets of a year-on-year revenue growth rate of no less than 13% or 18% from 2025 to 2027. Based on the normalization of medical consumables and the brand strength of consumer goods, it maintains a \"Buy\" rating"
datetime: "2025-06-11T07:46:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244018306.md)
  - [en](https://longbridge.com/en/news/244018306.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244018306.md)
generator: "portal-rs"
---

# Western Securities: Winner Medical's growth driven by both internal and external factors, maintaining a "Buy" rating

The research report from Western Securities points out that with the dual drivers of healthcare and consumption, Winner Medical is stabilizing and entering a growth year. In 2024, the company will launch an equity incentive plan, intending to grant 7.476 million restricted shares, accounting for approximately 1.28% of the company's total share capital. The performance assessment targets are that from 2025 to 2027, the revenue growth rate at the company level and for the two major business segments should not be less than 13% or 18% year-on-year, demonstrating the company's confidence in long-term development. Considering that the base of the company's medical consumables segment is returning to normal, the brand strength of consumer goods is prominent, and growth is driven by both internal and external factors, the rating is maintained at "Buy."

### Related Stocks

- [300888.CN](https://longbridge.com/en/quote/300888.CN.md)
- [002673.CN](https://longbridge.com/en/quote/002673.CN.md)

## Related News & Research

- [Vector Science begins pharma-grade peptide production at first LyoGenesis suite, targets 55,000 vials a month](https://longbridge.com/en/news/296780586.md)
- [Bizlink Holding Has Detected Parts Of Its Data Systems Have Been Compromised By Internet Security Incident](https://longbridge.com/en/news/296750112.md)
- [06:55 ETProtiviti Professionals Named 2026 Top Consultants by Consulting Magazine](https://longbridge.com/en/news/296776059.md)
- [Qualicorp releases 2Q26 institutional presentation factsheet](https://longbridge.com/en/news/296404030.md)
- [Tvardi Therapeutics: TTI-109 targets STAT3 to address unmet needs in UC with selective immune modulation and safety](https://longbridge.com/en/news/296374826.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**